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Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma 
Introduction
Cancer is a multistep, polygenic disease caused by accumulation of genetic alterations in oncogenes or tumor suppressor genes resulting in neoplastic transformation. Increasing evidence suggests that new and effective targets for diagnosis and therapy could be identified by mutation profiling of cancer genomes. A systematic analysis of 13,023 wellannotated human protein-coding genes, known as consensus coding sequences (CCDS) 1 was recently carried out by Sjöblom et al. 2 This strategy led to the identification of 1149 genes displaying somatic mutations. To distinguish genes likely to contribute to tumorigenesis from those in which passenger mutations occurred by chance, the authors used a statistical approach that allowed the definition of 189 candidate cancer (CAN) genes. To determine the significance of these findings in cancers other than breast and colon, we analyzed a subset of CAN genes in glioblastoma, melanoma, and pancreatic ductal adenocarcinoma (PDAC). These tumor types are known to be highly malignant and resistant to treatment. For example, metastatic melanoma has a poor prognosis, with a median survival of 6 to 9 months. 3 Glioblastoma is the most common brain tumor in adults and kills patients within a median of 14 months after diagnosis, even after surgical resection, radiotherapy, and concomitant chemotherapy. 4 PDAC is highly aggressive and resistant to conventional and targeted therapeutic agents, resulting in a dismal 5-year survival rate of 3% to 5%. 5 In this study, we present the mutational profile of 19 CAN genes in glioblastoma, melanoma, and PDAC. The candidate genes were selected either because they displayed a mutation frequency above 10%, or because multiple mutations affecting a single amino acid residue were previously found in the same gene. 2 Specifically, we examined the following genes and exons in which mutations have been recently described : ABCA1, ADAMTSL3, ATP8B1,  CUBN, DIP2C, EGFL6, EPHA3, EPHB6, FBXW7, FLNB,GNAS, MACF1, MLL3, OBSCN, PKHD1,  SPTAN1, SYNE1 , TECTA, and ZNF668. Details on genes and exons analyzed can be found in Supplementary Table S1 .
Materials and methods
Patients, tumor samples and DNA extraction Twenty-three human glioblastoma samples and the matched normal DNA were obtained from the tumor bank maintained by the Departments of Neurosurgery and Neuropathology at the Academic Medical Center (Amsterdam, The Netherlands). The glioblastoma cell line U87MG, officially known as an astrocytoma grade 3 cell line, was provided by Dr. C. van Bree (Department of Radiotherapy, Academic Medical Center). One of the changes we identified in EPHA3 (K500N) occurred in U87MG, for which no matched normal is available. Therefore, the somatic status of this mutation could not be ascertained. The melanoma and PDAC tumor samples and matched normals were obtained from the tumor banks maintained by the Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy and the Department of Pathology, Section of Anatomic Pathology, University of Verona, Verona, Italy, respectively ( Table 1) . Genomic DNA was isolated as previously described, 6 except for the PDAC samples that were isolated using DNeasy Blood & Tissue kit (Qiagen, Milan, Italy). For samples in which mutations were found, matching between germline and tumor DNA was verified by direct sequencing of 26 single nucleotide polymorphisms (SNPs) at 24 loci (data not shown). for 30 sec, followed by 70°C for 5 min and 12°C forever. PCR products were purified using AMPure® (Agencourt Bioscience Corporation, Beckman Coulter, Milan, Italy) and eluted in distilled water. Sequencing PCRs were carried out at 97°C for 3 min, and 29 cycles of 97°C for 10 sec, 50°C for 20 sec and 60°C for 2 min. Sequencing PCR products were purified using CleanSeq® (Agencourt Bioscience Corporation). Direct sequencing was performed using BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) with a 3730 DNA Analyzer, ABI capillary electrophoresis system (Applied Biosystems). Sequence traces were analyzed using Mutation Surveyor software (Version 2.02; SoftGenetics, State College, PA). Glioblastoma  T1  39  F  IV  PT  PT  blood  T03  52  F  IV  PT  PT  blood  T12  74  F  IV  PT  PT  blood  T37  69  F  IV  PT  PT  blood  T39  37  M  IV  PT  PT  blood  T52  72  F  IV  PT  PT  blood  T70  76  M  IV  PT  PT  blood  T71  66  F  IV  PT  PT  blood  T76  60  F  IV  PT  PT  blood  T79  54  F  IV  PT  PT  blood  T80  47  M  IV  PT  PT  blood  T83  52  M  IV  PT  PT  blood  T85  31  F  IV  PT  PT  blood  T86  73  M  IV  PT  PT  blood  T90  64  F  IV  PT  PT  blood  T91  64  M  IV  PT  PT  blood  T94  57  F  IV  PT  PT  blood  T99  62  F  IV  PT  PT  blood  T104  69  M  IV  PT  PT  blood  T105  41  M  IV  PT  PT  blood  T107  39  F  IV  PT  PT  blood  T111  46  F  IV  PT  PT  blood  T112  48  M  IV  PT  PT  blood  T113  40  M  IV  PT  PT  blood  U87MG*  44  F  III  PT  cell line  not available  Melanoma  2A  51  M  IV  NM  STC  EBL  4A  55  F  IIB/IIIC  PT  STC  EBL  5A  36  F  IIIB/IIIC  NM  STC  EBL  6A  43  M  IIIC  NM  STC  EBL  7A  22  F  IIIB/IIIC  NM  STC  EBL  8A  55  M  IIIC  NM  STC  EBL  9A  53  M  IIIB/IIIC  NM  STC  EBL  10A  52  M  IIIC  NM  STC  EBL  11A  69  M  IIIA/IIIB  NM  STC  EBL  12A  70  M  IV  CM  STC  EBL  13A  59  F  IV  CM  STC  EBL  14A  56  M  III  NM  STC  EBL  15A  30  M  IV-M 1c  COM  STC  EBL  16A  45  F  IIIB/IIIC  NM  STC  EBL  17A  51  M  IV  CM  STC  EBL  18A  68  M  IV  CM  STC  blood  19A  71  F  IIIC T 4a N 3 M 0  CM  STC  EBL  20A  24  M  IIIC  NM  STC  EBL  21A  36  F  IIIB/IIIC  NM  STC  EBL  22A  39  F  IIIC  NM  STC  blood  23A  56  M  IV-M 1c  LM  STC  EBL  24A  49  M  IV  CM  STC  EBL  25A  49  M  IV  CM  STC  EBL  26A  62  F  IV-M 
PCR and sequencing details

Results and discussion
A recent large-scale sequencing effort led to the identification of somatic mutations in more than 150 CAN genes in breast and CRC. 2 The detailed mutational status of these genes in other cancer types remains to be determined. In this study, we examined the mutational profile of 19 CAN genes in a panel of 24 glioblastoma, 24 melanomas, and 12 pancreatic cancers samples. The clinical information associated with these tumors is described in Table 1 . For each gene, all exons in which somatic mutations had previously been identified were analyzed. Exon specific primers were designed to amplify and sequence the coding region and at least 15 intronic bases at both the 5' and 3' ends, including the splicing donor and acceptor sites (Supplementary Table S1 ). A total of 7.798 PCR products, spanning 1.47 Mb of tumor genomic DNA, were generated and subjected to direct sequencing. A total of 2.743 nucleotide changes were identified during this initial screening. Changes previously described as SNPs were excluded from further analyses. 8 To ensure that the observed mutations were not PCR or sequencing artifacts, amplicons were independently re-amplified and resequenced in the corresponding tumors. All verified changes were resequenced in parallel with the matched normal DNA to distinguish between somatic mutations and SNPs not previously described.
This approach led to the identification of eight novel somatic mutations and one germline change in five CAN genes ( Table 2) . Three missense somatic mutations were found in EPHA3, two of which (K500N and A971P) were found in glioblastoma. The third EPHA3 mutation (G228R) was observed in a melanoma sample that also contained a missense mutation in OBSCN (E4574K). Two mutations were found in MLL3 in a glioblastoma (3614Ddel) and a PDAC sample (P1863A). In addition, one mutation each was found in FBXW7 (R473fs*23) and TECTA (P802S) in two melanoma samples. The observed mutation rate was higher than the expected passenger mutation rate (P < 0.01, binomial distribution). 9 In addition, we found a germline variant of a previously reported somatic mutation (R4558H) in OBSCN in a glioblastoma patient. 
Gene
Identified mutations in CAN genes
The genes and the type of mutations found are listed alongside the samples in which they were found. Zygosity for the mutations is shown.*Germline mutation.
One of the most interesting genes found mutated is the Ephrin receptor A3 (EPHA3).
EPHA3 is a member of the Ephrin receptor family, which forms the largest subgroup of the receptor tyrosine kinases. Ephrin receptors and their ligands (Ephrins) are essential for a variety of biological processes and are implicated in tumor growth and survival. 10 EPHA3, or human eph/elklike kinase, maps to chromosome 3p11.2, a region frequently affected in different cancers. 11 Mutations in EPHA3 in have been described in lung and colon cancer.
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Here, we report for the first time an EPHA3 mutation in melanoma. This mutation (G228R) occurs in a cysteine-rich linker region of the extracellular domain. Interestingly, this region is evolutionary conserved and may be important in determining the binding affinity to its particular ligand type. EPHA2 receptor antagonists have remarkable antiangiogenic and antitumor effects, suggesting that the EPHA signaling pathway represents an attractive novel target for cancer therapy. 15 The tyrosine kinase activity of the EPHA3 receptor may be therapeutically targeted. Therefore, for this gene only, we extended our analysis to all coding exons. Two additional EPHA3 mutations (K500N and A971P) were found in Figure 1A ) occurred in the sterile a-motif region. Both domains are highly conserved throughout evolution, suggesting that the changes affect critical functions of this gene.
We report for the first time somatic mutations in the interdomain regions of mixedlineage leukemia 3 (MLL3) gene in glioblastoma and PDAC cancer. MLL3, also designated as 'homologous to ALR' (HALR), is a member of the TRX/MLL gene family and maps to 7q36, a chromosome region that is frequently deleted in myeloid leukemia. 16 Members of the MLL family are often targets for translocations in leukemias, leading to oncogenic fusion proteins that are associated with an extremely poor prognosis. 17 TRX/MLL members serve as tumor suppressors, act as chromatin regulators, and play an important role during development. Interestingly, amplification of MLL2 has been reported in glioblastoma and pancreatic carcinoma cell lines. 18 Therefore, our results indicate that multiple members of the MLL family can be deregulated via different oncogenic mechanisms in these two cancer types.
The third gene in which we detected mutations was tectorin-α (TECTA) that was found altered in a melanoma sample. TECTA is the major non-collagenous component of the tectorial membrane of the inner ear. Mutations in TECTA have been shown to be responsible for autosomal dominant non-syndromic hearing impairments and a recessive form of sensorineural pre-lingual non-syndromic deafness. 19 The identified mutation, P802S (Figure 1B) , lies in the second von Willebrand factor type D domain and has not been described in any type of deafness. No previous association between TECTA and cancer has been reported.
The mutational profiling of FBXW7 resulted in the identification of the R473fs*23 mutation in a melanoma sample. F-box and WD-40 domain protein 7 (FBXW7 or hCDC4) is part of an ubiquitin ligase complex that targets molecules, such as cyclin E, Notch, c-Jun, and c-Myc, for degradation. 20 Inactivating mutations in FBXW7 have been previously described in a variety of human tumors and cancer cell lines. The nonsense mutation we found (R473fs*23) is located in the third of seven highly conserved WD40 repeats, known to serve as a protein binding platform. The deleted nucleotide is part of a codon formed by the last two bases of exon 9 and the first base of exon 10; therefore, a heterozygous deletion of the second last base of exon 9 causes a frameshift in exon 10. This leads to a premature stop codon, resulting in truncation of the protein, thereby potentially interrupting the binding to its substrate. 21 This change may, therefore, have direct functional implications, especially considering the putative haploinsufficient nature of this tumor suppressor gene. 20 One of the most intriguing results of this analysis is the identification of novel somatic and germline mutations in OBSCN. OBSCN encodes a RhoGEF protein that interacts with cytoskeletal calmodulin and titin and is part of the giant sarcomeric signaling protein family of myosin light chain kinases. Different isoforms have been described, containing functionally interesting domains, including two serine-threonine kinase domains, with a potential role in signal transduction. 22 The somatic mutation E4574K ( Figure 1C ) affects the fibronectin type-III domain 3, which is highly conserved throughout evolution. Thus far, OBSCN has been mainly known for its role in cardiac and skeletal muscle, where it is required for the assembly and organization of sarcomeres and the sarcoplasmic reticulum. 22 Mutations in other genes encoding the giant muscle proteins titin (TTN) and nebulin (NEB) have been associated with cardiac and skeletal myopathies in humans. Interestingly, OBSCN was reported to be interrupted by a t(1;7)(q42;p15) breakpoint, in a Wilms' tumor patient with thrombocytopenia-absent radius syndrome-like symptoms. 23 The recent identification of OBSCN somatic mutations in multiple cancer types indicates that this gene may play a role in different diseases. 2, 14 It is also interesting to note that of the 189 CAN genes identified in colon and breast, only TP53 and OBSCN were common to both tumor types. The identification of mutations in OBSCN and TTN in multiple cancer types, which now include melanoma and glioblastoma, suggests that the cellular functions of these partner molecules could be related to a common tumor progression mechanism.
In addition to the E4574K somatic mutation, we also found another germline change (R4558H) in OBSCN in a glioblastoma sample. Exactly the same change had been previously found to be a somatic mutation by Sjöblom et al.
2 Surprisingly, however, we found that the same change was also present in the matched normal DNA (obtained from the blood of the same patient), indicating that it was a germline rather than a somatic mutation ( Figure 1D) . The R4558H mutation is not a common SNP as it is absent from the publicly available databases. 24, 25 To further exclude the possibility that R4558H was a rare SNP, we sequenced another 359 human DNA samples again without finding this allele. Our results, therefore, suggest that the R4558H could be a germline cancer mutation. Importantly, the glioblastoma patient carrying the R4558H allele does not have a history of cardiac or skeletal muscle anomalies. This suggests that the R4558H mutation is not associated with the previously reported role of OBSCN in muscle tissues. The identification of germline and somatic mutations in OBSCN resembles what has been previously observed in other important cancer genes such as PTEN, RET, and TP53. In those cases, the very same mutations involved in the development of sporadic tumors were found to be cancer predisposing when present in the germline. It is conceivable that germline changes in OBSCN might also similarly predispose to cancer.
In conclusion, our data identify novel genes and their specific molecular alterations involved in glioblastoma, melanoma, and pancreatic cancers. None of the somatic mutations described by Sjöblom et al 2 were found in our analyses of glioblastoma, melanoma, and PDAC samples. These results, therefore, suggest that tumors have their own CAN genes, and only a few of the CAN genes are shared by different tumor types. In addition, the mutations themselves, rather than the genes, might be tumor-specific. With the exception of P1863A in MLL3, all the mutations we found were in heterozygous state. Interestingly, this is similar to the mutation pattern observed by Sjöblom et al. 2 The occurrence of heterozygous mutations is very common in oncogenes where they act in a dominant fashion. Alternatively, as previously shown for FBXW7, a haploinsufficient tumor suppressor, a heterozygous mutation may result in its inactivation. Because TECTA and OBSCN have not been previously associated with cancer, the effect of these mutations cannot presently be predicted. Some of the mutations we found affect genes (such as the tyrosine kinase EPHA3) that are clearly amenable to 51 pharmacologic intervention and therefore could represent novel therapeutic targets for these untreatable cancers. Finally, we speculate that similar to other oncogenes and tumor suppressor genes, mutations affecting OBSCN could be involved in cancer predisposition.
